Trials / Conditions / Microsatellite Stable Colorectal Cancer

Microsatellite Stable Colorectal Cancer

13 registered clinical trials studyying Microsatellite Stable Colorectal Cancer — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Suspended	Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab NCT07011550	M.D. Anderson Cancer Center	Phase 2
Recruiting	A Study of VET3-TGI in Patients With Solid Tumors NCT06444815	KaliVir Immunotherapeutics	Phase 1
Recruiting	FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264	Parabilis Medicines, Inc.	Phase 1 / Phase 2
Recruiting	A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709	Bristol-Myers Squibb	Phase 1 / Phase 2
Withdrawn	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC NCT04145193	MedImmune LLC	Phase 2
Completed	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NCT04332653	NeoImmuneTech	Phase 1 / Phase 2
Terminated	Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011	Turnstone Biologics, Corp.	Phase 1
Terminated	GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342	GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	Phase 1
Active Not Recruiting	Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tum NCT03891953	Novartis Pharmaceuticals	Phase 1
Completed	Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer NCT03658772	Arrys Therapeutics	Phase 1
Completed	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Se NCT03473925	Merck Sharp & Dohme LLC	Phase 2
Active Not Recruiting	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer NCT03104439	Massachusetts General Hospital	Phase 2
Completed	A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread NCT02060188	Bristol-Myers Squibb	Phase 2